Ligand Pharmaceuticals Inc.

476 articles with Ligand Pharmaceuticals Inc.

• Ligand to Report First Quarter Financial Results on May 3, 2021

  4/22/2021

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report financial results for the three months ended March 31, 2021 after the close of the U.S. financial markets on Monday, May 3, 2021 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg.

• Ligand Reports Fourth Quarter and Full Year 2020 Financial Results

  2/3/2021

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2020 and provided an operating forecast and program updates.

• Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

  2/2/2021

  Sparsentan achieved statistically significant response on interim proteinuria endpoint compared to irbesartan after 36-weeks of treatment To date in the study, sparsentan has been generally well-tolerated and has shown a safety profile comparable to irbesartan

• Ligand’s Fourth Quarter Financial Results to be Reported February 3rd

  1/20/2021

  Ligand’s Fourth Quarter Financial Results to be Reported February 3 rd

• Ligand Receives Milestone Payment from Merck

  1/13/2021

  Milestone payment triggered by acceptance for review of a BLA for V114, an investigational 15-valent pneumococcal conjugate vaccine that utilizes Ligand’s CRM197 carrier protein

• iMetabolic Biopharma Corporation Announces Expansion of its Strategic OmniAb Antibody Discovery Partnership with Ligand Pharmaceuticals Accelerating iMetabolic’s iPlatform™ Technology and Pipeline Development

  12/17/2020

  iMetabolic Biopharma Corporation (iMBP) announces expansion of its strategic partnership relationship with Ligand Pharmaceuticals, building on an earlier alliance agreement initiated in 2018, giving access to Ligand’s OmniAb platform. In this new agreement, iMBP gains access to additional OmniAb species and technologies, enabling the acceleration of iMBP’s development of assets through its iPlatform™ Technology. This stre

• Ligand’s Captisol Technology Plays Key Role in the Manufacture of Gilead’s Veklury, the First FDA-Approved COVID-19 Treatment

  10/23/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today highlighted the company’s role in the manufacturing of Veklury ® (remdesivir), Gilead Sciences’ antiviral drug for the treatment of patients with COVID-19 requiring hospitalization. Veklury is formulated with Ligand’s Captisol ® technology. Approved yesterday by the U.S. Food and Drug Administration, Veklury is the first and only approved COVID-19 treatment in the Un

• HitGen to Acquire Vernalis, a Leader in Structure-Based Drug Discovery

  10/12/2020

  HITGEN announces it has entered into a definitive agreement with Ligand Pharmaceuticals Inc. to acquire Vernalis Limited, Cambridge, UK-based world leaders in fragment and structure-based drug discovery research.

• Ligand to Divest Vernalis Research Operations

  10/12/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the sale of Ligand’s Vernalis research operations and internal programs to HitGen Inc. (SHA: 688222) for $25 million in cash. Under the terms of the agreement, Ligand will retain economic rights on complet

• Ligand to Host Virtual Investor Day on October 20th

  10/2/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the Company will be hosting a virtual Investor Day on Tuesday, October 20 th from 11:00 a.m. ET to approximately 1:00 p.m. ET. Presenting during the event will be: John Higgins, Chief Executive Officer Matt Foehr, President and Chief Operation Officer Matt Korenberg, Chief Financial Officer

• Ligand Completes Acquisition of Pfenex Inc.

  10/1/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced it has completed its tender offer for all outstanding shares of Pfenex Inc. for $437.5 million in cash, plus one non-transferable contingent value right (CVR) per share representing the right to receive a contingent payment of $78 million in cash if a certain specified milestone is achieved

• Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc.

  9/30/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Pfenex Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractual contingent value right per share representing the right to receive a contingent payment of $2.00 in cash, if a certain specified milesto

• Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million

  9/23/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that recent new contracting with partners and investments in manufacturing capacity have contributed to its Captisol business operating at the

• Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences

  9/10/2020

  Ligand Expands OmniAb ® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences The acquired technologies continue to position Ligand’s OmniAb as a best-in-class platform for antibody discovery

• Ligand Pharmaceuticals Management to Present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference

  9/1/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that senior management will present at an upcoming investor conference.

• Ligand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc.

  8/31/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its wholly-owned subsidiary, Pelican Acquisition Sub, Inc. (the “Purchaser”), is commencing a tender offer to purchase all outstanding shares of common stock of Pfenex, Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractual contingent value right per share representing the right to receive a cont

• Ligand OmniAb® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis

  8/25/2020

  Ligand OmniAb ® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis IMVT-1401 is a novel anti-FcRn OmniAb-derived antibody delivered by subcutaneous injection Registration-enabling Phase 3 trial expected to initiate in the first half of 2021 SAN DIEGO--( BUSINESS WIRE )-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) OmniAb® partner Immunovant, I

• Ligand Announces Amgen’s KYPROLIS® Approved by FDA as Combination Regimen with DARZALEX® and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myeloma

  8/24/2020

  Ligand Announces Amgen’s KYPROLIS ® Approved by FDA as Combination Regimen with DARZALEX ® and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myeloma KYPROLIS is an Amgen product that utilizes Captisol ® in its formulation Approval based on the CANDOR and EQUULEUS Studies SAN DIEGO--( BUSINESS WIRE )-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that a major Capti

• 

  Ligand Buys Pfenex in $516 Million Deal to Access Protein Production Platform

  8/11/2020

  Pfenex’ proprietary protein production platform, Pfenex Expression Technology, is used to improve existing treatments and create novel therapies.

• CStone Announces That OmniAb-derived CS1001 (Anti-PD-L1) Phase 3 Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Announces Plans to Submit a New Drug Application

  8/7/2020

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces CStone Pharmaceuticals (“CStone”, HKEX: 2616) recently reported that its OmniAb-derived anti-PD-L1 mAb CS1001 combined with platinum-based chemotherapy met its pre-specified primary endpoint, as assessed by the independent Data Monitoring Committee at the planned interim analysis of CS1001-302, a randomized, double-blind Phase 3 clinical trial for the first-line treatment of stage IV squamous